Question explored with the scientific record
How to rapper off long term pregabalin use of 200mg 3 times a day for nerve pain to replace pregabalin with an alternative?
The short version: tapering off 600 mg/day of pregabalin is a serious withdrawal risk, and the evidence for any single replacement drug is thin.
You are on a high dose. 200 mg three times a day is 600 mg total, which is above the typical maximum of 450 mg/day studied in trials [2]. Stopping or cutting too fast can cause severe withdrawal: anxiety, insomnia, sweating, and in rare cases seizures. The evidence here does not give a taper schedule, but general clinical practice is to reduce by no more than 50-75 mg every week. Do not attempt this without a doctor who understands the risk.
The evidence for alternatives is weak. The BMJ review shows pregabalin works for some nerve pain types, but the number needed to treat (NNT) is high: about 4 people need treatment for one to get meaningful relief in post-herpetic neuralgia, and about 8 for diabetic neuropathy [3]. That means most people get no real benefit. The same review found gabapentin has similar modest effects [3]. Oxcarbazepine, a drug sometimes used for trigeminal neuralgia, has some open-label data for nerve pain but no large placebo-controlled trials for general neuropathic pain [9]. Botulinum toxin injections have moderate evidence for trigeminal and post-herpetic neuralgia from small trials, but that is a very different delivery than a daily pill [11].
The table below shows the modest benefit of pregabalin itself from the best available trial, a manufacturer-funded study in fibromyalgia [2]. Notice that even at 450 mg/day, the average pain reduction was only about 1.5 points on a 10-point scale, and the placebo group dropped about 1 point. The drug effect over placebo was less than half a point.
| Measure | Pregabalin 450 mg/day | Placebo | Difference |
|---|---|---|---|
| Average pain reduction (0-10 scale) | -1.48 | -1.03 | -0.45 |
| Patients with 50% pain relief | 22.8% | 12.1% | 10.7% |
| Number needed to treat (NNT) for 50% relief | - | - | 10 |
My call: the evidence does not support a clean switch to a single alternative drug with proven efficacy for general neuropathic pain. The best path is a very slow taper under medical supervision, combined with non-drug approaches like physical therapy, sleep hygiene, and dietary changes that support nerve health. Confidence: moderate that the taper is necessary; low that any replacement drug will work as well as the modest effect you are already getting.
Sources used 4
-
A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia
This randomized, double-blind, multicenter phase III trial in Japan shows that pregabalin up to 450 mg/day significantly reduces pain and improves sleep and functioning in Japanese patients with fibromyalgia, with a manageable safety profile.
DOI: 10.1186/ar4056 -
Pregabalin and gabapentin for pain
This BMJ Practice article reviews the evidence from randomized trials and systematic reviews on pregabalin and gabapentin for pain, confirming efficacy for certain neuropathic pains but not for others, and detailing safety concerns, misuse risk, and practical prescribing conside…
DOI: 10.1136/bmj.m1315 -
Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain
A focused review of oxcarbazepine as a potentially safer and effective analgesic for neuropathic pain, detailing its pharmacology and clinical evidence in trigeminal neuralgia and painful diabetic neuropathy, including open-label and randomized trials that compare it to carbamaz…
DOI: 10.1016/s0885-3924(03)00067-8 -
The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses
A systematic review and meta-analysis of six randomized, double-blind, placebo-controlled trials finds that botulinum toxin type A reduces pain in trigeminal neuralgia and postherpetic neuralgia compared with placebo, with moderate evidence for a clinically meaningful effect but…
DOI: 10.1016/j.oooo.2016.03.003